Structure Therapeutics stock jumps 8% on promising weight loss drug results

Structure Therapeutics saw its stock climb by around 8% on Monday after releasing strong phase 2 results for its weight loss drug, aleniglipron. The latest data showed significant and sustained reductions in body weight across multiple studies. Investors reacted positively to the findings, which included long-term benefits from extended treatment.

The company's ACCESS II trial tested aleniglipron at doses of 180 mg and 240 mg over 44 weeks. Patients on these doses achieved placebo-adjusted weight loss of 16.3% and 16%, respectively. No signs of a weight loss plateau appeared during the study.

In an open-label extension, participants receiving 120 mg of alenigliptin continued losing weight for up to 56 weeks, reaching reductions of 16.2%. The results came from three key studies: the 44-week ACCESS II trial, an interim body composition analysis, and the ongoing open-label extension. Structure Therapeutics now plans to launch phase 3 trials in the second half of this year. The announcement follows a year of dramatic stock growth, with shares rising roughly 184% from late 2025 to early 2026. The price peaked near $94.90 before settling around $63.38 in mid-March, reflecting a period of adjustment after December's positive phase 2 updates.

The latest findings reinforce aleniglipron's potential as a long-term weight loss treatment. With phase 3 trials on the horizon, the drug's progress will be closely watched. The company's stock performance highlights investor confidence in its development pipeline.